What do you like doing in your spare time?
carafate 1gm tablets The technology has now been licensed to Swiss drugmakerNovartis AG (NOVN) to open international trials, said researcher Carl June, a professor of immunotherapy at the University of Pennsylvania. Multicenter trials will start in the U.S. next year at 8 centers around the country, and international trials should begin in 2014, he said.